These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 35696967

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
    Arvanitakis A, Berntorp E, Astermark J.
    Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
    [Abstract] [Full Text] [Related]

  • 7. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
    Matino D, Germini F, Chan AKC, Decker K, Iserman E, Chelle P, Edginton AN, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A.
    Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
    Gruppo R, López-Fernández MF, Wynn TT, Engl W, Sharkhawy M, Tangada S.
    Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
    Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A.
    Clin Pharmacokinet; 2020 Feb; 59(2):245-256. PubMed ID: 31435896
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective.
    Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME.
    Crit Rev Oncol Hematol; 2022 Jun; 174():103678. PubMed ID: 35390452
    [Abstract] [Full Text] [Related]

  • 18. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
    Sun SX, Frick A, Balasa V, Roberts JC.
    Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
    [Abstract] [Full Text] [Related]

  • 19. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
    Astermark J, Olsson A, Chelle P, Täckström K, Walger M, Magnusson M, Iorio A.
    Haemophilia; 2021 Jul; 27(4):626-633. PubMed ID: 33966319
    [Abstract] [Full Text] [Related]

  • 20. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C, Hoffmann I, Davidson S, Tiede A, Richter N.
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.